FDA approves Sunharbo, factor XIa inhibitor for reducing stroke
The FDA has approved Sunharbo, the only approved factor XIa inhibitor intended to reduce the risk for stroke in adults who recently experienced a non-cardioembolic ischemic stroke or high-risk transient ischemic attack. With the approval, physicians now have a treatment option that can lower patient risk for secondary stroke, which can come with more severe outcomes than incident strokes, said Ashkan Shoamanesh, MD, senior scientist with the Population Health Research…